Header Logo

Connection

Mary Rusckowski to Humans

This is a "connection" page, showing publications Mary Rusckowski has written about Humans.
Connection Strength

0.191
  1. Chen L, Wang Y, Cheng D, Dou S, Liu X, Liu G, Hnatowich DJ, Rusckowski M. Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents. Nucl Med Commun. 2011 Oct; 32(10):920-4.
    View in: PubMed
    Score: 0.015
  2. Xiao N, Cheng D, Wang Y, Chen L, Liu X, Dou S, Liu G, Liang M, Hnatowich DJ, Rusckowski M. Identification of a high affinity TAG-72 binding peptide by phage display selection. Cancer Biol Ther. 2011 Jan 01; 11(1):22-31.
    View in: PubMed
    Score: 0.014
  3. Chen L, Wang Y, Liu X, Dou S, Liu G, Hnatowich DJ, Rusckowski M. A new TAG-72 cancer marker peptide identified by phage display. Cancer Lett. 2008 Dec 08; 272(1):122-32.
    View in: PubMed
    Score: 0.012
  4. Rusckowski M, Gupta S, Liu G, Dou S, Hnatowich DJ. Evidence of specificity of radiolabeled phage display peptides for the TAG-72 antigen. Cancer Biother Radiopharm. 2007 Aug; 22(4):564-72.
    View in: PubMed
    Score: 0.011
  5. Lee PJ, Kennedy Z, Wang Y, Lu Y, Cefaliello C, Uyan ?, Song CQ, Godinho BMC, Xu Z, Rusckowski M, Xue W, Brown RH. Imaging Net Retrograde Axonal Transport In Vivo: A Physiological Biomarker. Ann Neurol. 2022 05; 91(5):716-729.
    View in: PubMed
    Score: 0.008
  6. Rusckowski M, Qu T, Pullman J, Marcel R, Ley AC, Ladner RC, Hnatowich DJ. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J Nucl Med. 2000 Feb; 41(2):363-74.
    View in: PubMed
    Score: 0.007
  7. Hnatowich DJ, Chang F, Qu T, Rusckowski M. Technetium-99m labeled peptides--an investigation of multiple HPLC peaks. Appl Radiat Isot. 1999 May; 50(5):911-21.
    View in: PubMed
    Score: 0.006
  8. Hnatowich DJ, Qu T, Chang F, Ley AC, Ladner RC, Rusckowski M. Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. J Nucl Med. 1998 Jan; 39(1):56-64.
    View in: PubMed
    Score: 0.006
  9. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res. 1997 Nov; 50(5):393-401.
    View in: PubMed
    Score: 0.006
  10. Rusckowski M, Paganelli G, Hnatowich DJ, Magnani P, Virzi F, Fogarasi M, DiLeo C, Sudati F, Fazio F. Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. J Nucl Med. 1996 Oct; 37(10):1655-62.
    View in: PubMed
    Score: 0.005
  11. Dou S, Wang Y, Barton B, Chen L, Rusckowski M, Shultz LD, Greiner DL, Liu G. Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach. Nucl Med Biol. 2014 Jan; 41(1):127-31.
    View in: PubMed
    Score: 0.004
  12. Liu X, Nakamura K, Cheng D, Peng C, Xiao N, Liu Y, Chen L, Rusckowski M, Hnatowich DJ. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle. Curr Drug Deliv. 2012 Jul; 9(4):431-6.
    View in: PubMed
    Score: 0.004
  13. Liu G, Dou S, Akalin A, Rusckowski M, Streeter PR, Shultz LD, Greiner DL. Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody. Nucl Med Biol. 2012 Jul; 39(5):645-51.
    View in: PubMed
    Score: 0.004
  14. Liu Y, Cheng D, Liu X, Liu G, Dou S, Xiao N, Chen L, Rusckowski M, Hnatowich DJ. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation. Nucl Med Biol. 2012 Jan; 39(1):101-7.
    View in: PubMed
    Score: 0.004
  15. Liu G, Dou S, Cheng D, Leif J, Rusckowski M, Streeter PR, Shultz LD, Hnatowich DJ, Greiner DL. Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model. Mol Pharm. 2011 Jun 06; 8(3):767-73.
    View in: PubMed
    Score: 0.004
  16. Liang M, Liu X, Liu G, Dou S, Cheng D, Liu Y, Rusckowski M, Hnatowich DJ. Reducing the background fluorescence in mice receiving fluorophore/inhibitor DNA duplexes. Mol Pharm. 2011 Feb 07; 8(1):126-32.
    View in: PubMed
    Score: 0.003
  17. Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Cancer Biother Radiopharm. 2010 Dec; 25(6):757-62.
    View in: PubMed
    Score: 0.003
  18. Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Oct 15; 10(8):767-74.
    View in: PubMed
    Score: 0.003
  19. Liang M, Liu X, Cheng D, Liu G, Dou S, Wang Y, Rusckowski M, Hnatowich DJ. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem. 2010 Jul 21; 21(7):1385-8.
    View in: PubMed
    Score: 0.003
  20. Liu X, Nakamura K, Wang Y, Cheng D, Liang M, Xiao N, Chen L, Rusckowski M, Hnatowich DJ. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle. J Biomed Nanotechnol. 2010 Apr; 6(2):153-7.
    View in: PubMed
    Score: 0.003
  21. Liu G, Dou S, Rusckowski M, Greiner D, Hnatowich D. Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation. Appl Radiat Isot. 2010 Sep; 68(9):1709-14.
    View in: PubMed
    Score: 0.003
  22. Wang Y, Liu X, Chen L, Cheng D, Rusckowski M, Hnatowich DJ. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur J Nucl Med Mol Imaging. 2009 Dec; 36(12):1977-86.
    View in: PubMed
    Score: 0.003
  23. Wang Y, Liu X, Nakamura K, Chen L, Rusckowski M, Hnatowich DJ. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles. Cancer Biother Radiopharm. 2009 Oct; 24(5):573-8.
    View in: PubMed
    Score: 0.003
  24. Liang M, Liu X, Cheng D, Nakamura K, Wang Y, Dou S, Liu G, Rusckowski M, Hnatowich DJ. Optical antisense tumor targeting in vivo with an improved fluorescent DNA duplex probe. Bioconjug Chem. 2009 Jun; 20(6):1223-7.
    View in: PubMed
    Score: 0.003
  25. Chen X, Dou S, Liu G, Liu X, Wang Y, Chen L, Rusckowski M, Hnatowich DJ. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem. 2008 Aug; 19(8):1518-25.
    View in: PubMed
    Score: 0.003
  26. Liu X, Wang Y, Nakamura K, Liu G, Dou S, Kubo A, Rusckowski M, Hnatowich DJ. Optical antisense imaging of tumor with fluorescent DNA duplexes. Bioconjug Chem. 2007 Nov-Dec; 18(6):1905-11.
    View in: PubMed
    Score: 0.003
  27. He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich D. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem. 2007 May-Jun; 18(3):983-8.
    View in: PubMed
    Score: 0.003
  28. Liu G, Dou S, Yin D, Squires S, Liu X, Wang Y, Rusckowski M, Hnatowich DJ. A novel pretargeting method for measuring antibody internalization in tumor cells. Cancer Biother Radiopharm. 2007 Feb; 22(1):33-9.
    View in: PubMed
    Score: 0.003
  29. Wang Y, Liu X, Zhang Y, Liu G, Rusckowski M, Hnatowich DJ. Nonspecific cellular accumulation of 99mTc-labeled oligonucleotides in culture is influenced by their guanine content. Nucl Med Biol. 2007 Jan; 34(1):47-54.
    View in: PubMed
    Score: 0.003
  30. Liu X, Nakamura K, Wang Y, Zhang S, He J, Liu G, Dou S, Kubo A, Rusckowski M, Hnatowich D. Improved delivery in cell culture of radiolabeled antisense DNAs by duplex formation. Mol Imaging Biol. 2006 Sep-Oct; 8(5):278-83.
    View in: PubMed
    Score: 0.003
  31. Liu X, Nakamura K, Wang Y, Wang Y, Liu G, He J, Ding H, Lu P, Rusckowski M, Kubo A, Hnatowich DJ. Initial mechanistic studies of antisense targeting in cells. J Nucl Med. 2006 Feb; 47(2):360-8.
    View in: PubMed
    Score: 0.002
  32. Zhang YM, Tung CH, He J, Liu N, Yanachkov I, Liu G, Rusckowski M, Vanderheyden JL. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Nucl Med Biol. 2006 Feb; 33(2):263-9.
    View in: PubMed
    Score: 0.002
  33. Rusckowski M, Doherty PW, Virzi F, Hnatowich DJ. A simple in vitro method of screening panels of monoclonal antibodies for tumor binding. J Immunol Methods. 1985 Feb 11; 76(2):375-82.
    View in: PubMed
    Score: 0.002
  34. Zhang Y, He J, Liu G, Venderheyden JL, Gupta S, Rusckowski M, Hnatowich DJ. Initial observations of 99mTc labelled locked nucleic acids for antisense targeting. Nucl Med Commun. 2004 Nov; 25(11):1113-8.
    View in: PubMed
    Score: 0.002
  35. He J, Liu G, Gupta S, Zhang Y, Rusckowski M, Hnatowich DJ. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. J Nucl Med. 2004 Jun; 45(6):1087-95.
    View in: PubMed
    Score: 0.002
  36. Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, Hnatowich DJ. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging. 2004 Mar; 31(3):417-24.
    View in: PubMed
    Score: 0.002
  37. Ferro-Flores G, Arteaga de Murphy C, Pedraza-L?pez M, Mel?ndez-Alafort L, Zhang YM, Rusckowski M, Hnatowich DJ. In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nucl Med Biol. 2003 Aug; 30(6):597-603.
    View in: PubMed
    Score: 0.002
  38. Su ZF, He J, Rusckowski M, Hnatowich DJ. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol. 2003 Feb; 30(2):141-9.
    View in: PubMed
    Score: 0.002
  39. Liu CB, Liu GZ, Liu N, Zhang YM, He J, Rusckowski M, Hnatowich DJ. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc. Nucl Med Biol. 2003 Feb; 30(2):207-14.
    View in: PubMed
    Score: 0.002
  40. Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem. 2002 May-Jun; 13(3):561-70.
    View in: PubMed
    Score: 0.002
  41. Zhang YM, Wang Y, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. In vitro investigations of tumor targeting with (99m)Tc-labeled antisense DNA. J Nucl Med. 2001 Nov; 42(11):1660-9.
    View in: PubMed
    Score: 0.002
  42. Mang'era KO, Liu G, Yi W, Zhang Y, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications. Eur J Nucl Med. 2001 Nov; 28(11):1682-9.
    View in: PubMed
    Score: 0.002
  43. Chang F, Qu T, Rusckowski M, Hnatowich DJ. NHS-MAS3: a bifunctional chelator alternative to NHS-MAG3. Appl Radiat Isot. 1999 Apr; 50(4):723-32.
    View in: PubMed
    Score: 0.002
  44. Chang F, Rusckowski M, Qu T, Hnatowich DJ. Early results in the irrational design of new bifunctional chelators. Cancer. 1997 Dec 15; 80(12 Suppl):2347-53.
    View in: PubMed
    Score: 0.001
  45. Mardirossian G, Lei K, Rusckowski M, Chang F, Qu T, Egholm M, Hnatowich DJ. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med. 1997 Jun; 38(6):907-13.
    View in: PubMed
    Score: 0.001
  46. Hnatowich DJ, Mardirossian G, Rusckowski M, Roy S, Bushe H, Griffin TW, Brill AB. Pharmacokinetics of the FO23C5 anti-CEA antibody fragment labelled with 99Tcm and 111In: a comparison in patients. Nucl Med Commun. 1993 Jan; 14(1):52-63.
    View in: PubMed
    Score: 0.001
  47. Mardirossian G, Wu C, Rusckowski M, Hnatowich DJ. The stability of 99Tcm directly labelled to an Fab' antibody via stannous ion and mercaptoethanol reduction. Nucl Med Commun. 1992 Jul; 13(7):503-12.
    View in: PubMed
    Score: 0.001
  48. Hnatowich DJ, Rusckowski M, Siebecker DA, Gionet M, Mardirossian G, Bushe HS, Roy S, Mattis JA, Shealy D, Griffin TW, et al. Pharmacokinetics of indium-111 labeled 10-3D2 antibreast-tumor antibody in patients. J Nucl Biol Med (1991). 1992 Jan-Mar; 36(1):7-13.
    View in: PubMed
    Score: 0.001
  49. Griffin TW, Brill AB, Stevens S, Collins JA, Bokhari F, Bushe H, Stochl MC, Gionet M, Rusckowski M, Stroupe SD, et al. Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer. J Clin Oncol. 1991 Apr; 9(4):631-40.
    View in: PubMed
    Score: 0.001
  50. Hnatowich DJ, Rusckowski M, Brill AB, Siebecker DA, Misra H, Mardirossian G, Bushe H, Rescigno A, Stevens S, Johnson DK, et al. Pharmacokinetics in patients of an anti-carcinoembryonic antigen antibody radiolabeled with indium-111 using a novel diethylenetriamine pentaacetic acid chelator. Cancer Res. 1990 Nov 15; 50(22):7272-8.
    View in: PubMed
    Score: 0.001
  51. Kalofonos HP, Rusckowski M, Siebecker DA, Sivolapenko GB, Snook D, Lavender JP, Epenetos AA, Hnatowich DJ. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990 Nov; 31(11):1791-6.
    View in: PubMed
    Score: 0.001
  52. Rescigno A, Bushe H, Brill AB, Rusckowski M, Griffin TW, Hnatowich DJ. Pharmacokinetic modeling of radiolabeled antibody distribution in man. Am J Physiol Imaging. 1990; 5(4):141-50.
    View in: PubMed
    Score: 0.001
  53. Hnatowich DJ, Gionet M, Rusckowski M, Siebecker DA, Roche J, Shealy D, Mattis JA, Wilson J, McGann J, Hunter RE, et al. Pharmacokinetics of 111In-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody. Cancer Res. 1987 Nov 15; 47(22):6111-7.
    View in: PubMed
    Score: 0.001
  54. Hnatowich DJ, Griffin TW, Kosciuczyk C, Rusckowski M, Childs RL, Mattis JA, Shealy D, Doherty PW. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med. 1985 Aug; 26(8):849-58.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.